MEMPHASYS LIMITED. — Capital/Financing Update 2013

Jul 22, 2013

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

Section 708A SPP Cleansing Statement

Sydney, Australia 23[rd] July 2013–NuSep (ASX:NSP). This notice is given by NuSep Holdings Ltd (the Company ) under section 708A(5)(e) of the Corporations Act 2001 (cth) (the Corporations Act ). The Company will issue up to 41,448,942 fully paid shares in the capital of NuSep ( New Shares ), under its Share Purchase Plan ( SPP ) announced to the ASX on Monday 22[nd] July 2013.

The Company advises as follows:

• a) The New Shares will be issued under a share purchase plan without disclosure to investors under Part 6D.2 of the Act;

• b) This notice is being given in compliance with the requirements of Part 6D.2 of the Act, as modified by ASIC Class Order 09/425;

• c) As at the date of this notice, the Company has complied with:

• i. The provisions of Chapter 2M of the Corporations Act as they relate to the Company; and

• ii. Section 674 of the Corporations Act; and

• d) As at the date of this notice, there is no “excluded information” which is required to be set out in this notice pursuant to section 708A(7) or Section 708A(8) of the Corporations Act.

Yours sincerely,

Prakash Patel Managing Director

- END -

For more information please contact:

Contact: Prakash Patel Managing Director +61 2 8415 7300

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

Contact Details Email info@nusep.com Telephone +61 2 8415 7300 Web www.nusep.com Facsimile +61 2 8415 7399 ABN 33 120 047 556

NuSep Holdings Ltd 30 Richmond Rd Homebush NSW 2140

Postal Address P.O. Box 2202 Homebush West NSW 2140

– 2 –

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME[1] technology. The PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. NuSep has a 90% shareholding in PrIME Biologics. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.

1 PrIME stands for Pr eparative I solation by M embrane E lectrophoresis